{"id":821,"date":"2025-09-08T15:00:20","date_gmt":"2025-09-08T14:00:20","guid":{"rendered":"https:\/\/nailarabbani.com\/?p=821"},"modified":"2025-11-11T16:36:36","modified_gmt":"2025-11-11T15:36:36","slug":"a-breakthrough-in-autism-science-biomarkers-as-the-future-of-diagnosis","status":"publish","type":"post","link":"https:\/\/nailarabbani.com\/index.php\/2025\/09\/08\/a-breakthrough-in-autism-science-biomarkers-as-the-future-of-diagnosis\/","title":{"rendered":"A Breakthrough in Autism Science: Biomarkers as the Future of Diagnosis"},"content":{"rendered":"

When I first began researching autism more than a decade ago, one question kept me awake at night: Could we find an objective, biological way to diagnose autism spectrum disorder (ASD)?<\/em><\/p>\n

For families, the diagnostic journey can be long, uncertain, and emotionally draining. Current methods depend heavily on behavioral observation and developmental assessments, which\u2014though valuable\u2014are subjective and often vary from one clinician to another. The absence of a clear laboratory test has left parents searching for certainty, and doctors wishing for a more precise tool.<\/p>\n

This is where biomarkers enter the story.<\/p>\n

What Are Biomarkers, and Why Do They Matter?<\/h2>\n

A biomarker is a measurable biological signal\u2014something in the blood, urine, or tissues that reflects a process happening in the body. In diabetes, for example, blood sugar and HbA1c are trusted biomarkers. In heart disease, cholesterol levels are widely used.<\/p>\n

For autism, we asked: Could there be reliable biochemical fingerprints that reveal the condition, much like a blood test can reveal diabetes?<\/em><\/p>\n

The promise of biomarkers lies not just in diagnosis but in objectivity<\/strong>. They provide measurable, reproducible evidence\u2014reducing uncertainty for families, helping clinicians act with confidence, and enabling earlier interventions for children.<\/p>\n

The 2018 Discovery: Opening a Door \u00a0\u00a0 \u00a0IMG_5795<\/a><\/h2>\n

In 2018, my colleagues and I published a study in Molecular Autism<\/em> that offered the first real evidence that autism might leave a trace in the body\u2019s chemistry.<\/p>\n

We found that children with ASD showed higher levels of certain advanced glycation endproducts (AGEs)<\/strong> and oxidative stress markers<\/strong> such as dityrosine<\/strong>. These molecules form when sugar metabolism goes awry, creating a toxic stress environment in cells.<\/p>\n

Even more striking was how well these markers could distinguish children with autism from those without. Using machine learning to combine the data, we achieved over 90% sensitivity<\/strong> and 84% specificity<\/strong>\u2014numbers that hinted at the possibility of a blood test for autism.<\/p>\n

For the first time, we glimpsed a future where diagnosis could be supported by biochemistry, not just observation.<\/p>\n

The 2023 Validation: From Theory to Clinical Reality<\/h2>\n

But in science, discovery must be tested, challenged, and validated. That is exactly what we did in our follow-up study, published in Molecular Psychiatry<\/em> in 2023.<\/p>\n

This time, we worked with a much larger and more diverse group\u2014478 children, from 1.5 to 12 years of age, across Qatar and Spain. The results reaffirmed our earlier findings: biomarkers of glycation and oxidation were consistently elevated in children with ASD.<\/p>\n

Even more importantly, we discovered that these biomarkers were not only linked to the presence of autism but also correlated with its severity<\/strong>. Children with higher levels of certain markers, such as methylglyoxal-derived adducts<\/strong>, often showed more severe symptoms.<\/p>\n

This was the breakthrough: a validated panel of biomarkers that could help both in diagnosis<\/strong> and in understanding causes and severity<\/strong>.<\/p>\n

Why This Changes the Future of Autism Care<\/h2>\n

Imagine a world where a simple blood test could:<\/p>\n